QUOTE AND NEWS
StreetInsider.com  Oct 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catyalyst+Pharmaceutical+%28CPRX%29+to+Update+on+Firdapse+Phase+3+at+AANEM/9942478.html for the full story.
Forbes  Oct 8  Comment 
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they...
TheStreet.com  Sep 30  Comment 
NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partnersa shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 andareiterated its "buy" rating. The upgraded outlook stems from Catalyst's...
SeekingAlpha  Sep 30  Comment 
By Alexander Maxwell: Shareholders in Catalyst Pharmaceutical Partners (NASDAQ:CPRX) received some welcome news yesterday, as the company announced that the clinical trial for its drug Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS) was a...
StreetInsider.com  Sep 30  Comment 
The following is a list of notable articles to help get you through the lunch hour: Investors Could Reap Billions in Yahoo! (YHOO) Breakup -> Read this! Aegis Capital Raises PT on CAMAC (CAK) to $1.50; Notes Increase in Recoverable Prospective...
StreetInsider.com  Sep 29  Comment 
Catyalyst Pharmaceutical (NASDAQ: CPRX) 19.7% HIGHER; announced positive top-line results from the pivotal Phase 3 clinical trial of Firdapse (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of...
FierceBiotech  Sep 29  Comment 
Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.
StreetInsider.com  Sep 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Catyalyst+Pharmaceutical+%28CPRX%29+Reports+Firdapse+Met+co-Primary%2C+Secondary+Endpoints+in+Pivotal+Phase+3/9868035.html for the full story.
Benzinga  Sep 2  Comment 
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of its second Phase 1...
Benzinga  Aug 11  Comment 
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the progress of its Phase 3...





You may also be interested in articles related to Catalyst Pharmaceutical Partners (CPRX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki